Aptamer-Based Immunotheranostic Strategies

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer progression involves immune evasion through immune checkpoints like PD-1, PD-L1, CTLA-4, LAG-3, and TIM-3.
• Current immunotherapies targeting these checkpoints show variable clinical responses, necessitating novel strategies.
• Theranostics and aptamers present emerging solutions for enhanced cancer treatment and monitoring.

Approach:

• Aptamers, as single-stranded oligonucleotides, possess high affinity and specificity for molecular targets.
• Their small size and unique structure facilitate versatile theranostic applications.
• This review focuses on aptamer-based theranostic strategies targeting immune checkpoints.

Key Points:

• Aptamers offer precise targeting of immune checkpoint molecules involved in cancer immune evasion.
• Their characteristics enable the development of novel theranostic tools for cancer immunotherapy.
• Advancements in aptamer technology hold significant potential for personalized cancer treatment.

Conclusions:

• Aptamer-based theranostics represent a promising frontier in overcoming challenges in cancer immunotherapy.
• Targeting immune checkpoints with aptamers could lead to improved patient outcomes.
• Further research into aptamer theranostics is crucial for realizing their full clinical potential.